Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Teva Pharmaceutical Industries Ltd. ADR-1.50% $19.99B ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

The Food and Drug Administration on Friday gave a green light to a new meningococcal vaccine from GSK. Dubbed Penmenvy, the “5-in-1” shot is approved for people aged 10 through 25 years old and ...

Morgan Stanley initiated coverage of GSK (GSK) with an Equal Weight rating and 1,450 GBp price target The shares trade at an inexpensive valuation but the company’s mid- to longer-term growth ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

The Food and Drug Administration (FDA) announced that Penmenvy will be allowed for use in individuals aged 10-to-25 years old following two successful Phase III trials. GSK said safety data from ...